Von Willebrand Disease Clinical Trial
Official title:
Von Willebrand Disease in the Netherlands - Prospective Study (WiN-Pro)
The primary aim of this study is to prospectively investigate the current bleeding tendency of children and adults with VWD.
Von Willebrand disease (VWD) is the most common inherited bleeding disorder, and is
characterized by a defective platelet adhesion and aggregation. VWD is caused by a reduced
(type 1), an abnormal function (type 2) or a complete absence (type 3) of von Willebrand
factor (VWF).
In recent years, large retrospective cohort studies have provided valuable insights on the
clinical presentation, bleeding phenotype, quality of life, diagnostics, genetics and
treatment of patients with VWD. One of these large studies is the von Willebrand in the
Netherlands (WiN) study, which is a nationwide cross sectional study of moderate and severe
von Willebrand disease patients, that was initiated in 2007. Over 800 VWD patients were
included in the WiN study, which was about 80% of all known VWD patients in the Netherlands.
Although the WiN study and large retrospective studies in other countries provided important
insights in understanding VWD, some significant challenges remain and large prospective
studies are lacking to provide answers.
All large retrospective cohort studies have assessed the bleeding phenotype of patients with
VWD using bleeding scores or retrospective questionnaires. Bleeding scores calculate the sum
of all bleeding episodes during lifetime. Therefore, they provide useful information on the
bleeding tendency during lifetime. However, bleeding scores do not provide information on the
change of bleeding tendency. If a patient had a period in his or her lifetime in which he or
she had many bleeding episodes, then the bleeding score is high. Though, the patient could
have had those bleeds 30 years ago and did not have a bleeding episode since then. Therefore,
bleeding scores do not provide information on the current bleeding phenotype of VWD patients.
Furthermore, previous studies provided limited information on the frequency of mild
bleedings, like gum bleeding or epistaxis, that occur in daily life but do not require
therapy. Nevertheless, these bleeding episodes can cause a major impairment in quality of
life. This is especially important in children, because school-going children with VWD have a
lower quality of life and have a different bleeding tendency, characterized by more cutaneous
bleeding (81%), oropharyngeal bleeding (64%) and epistaxis (56%).
Therefore, the primary aim of this study is to prospectively investigate the current bleeding
tendency of children and adults with VWD.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Withdrawn |
NCT01651468 -
The Effect of the Nutraceutical "Hemofix" on the Coagulation System
|
N/A | |
| Active, not recruiting |
NCT00555555 -
Efficacy of Alphanate FVIII/VWF Concentrate in Type 3 Von Willebrand Patients
|
Phase 4 | |
| Terminated |
NCT00178542 -
Change in Thrombin Generation Potential and Thromboelastography During the Menstrual Cycle
|
N/A | |
| Completed |
NCT02552576 -
Study of Voncento® in Subjects With Von Willebrand Disease
|
Phase 4 | |
| Recruiting |
NCT02869074 -
Molecular and Clinical Profile of Von Willebrand Disease in Spain
|
||
| Completed |
NCT01602419 -
Surveillance of Safety and Efficacy of Wilate in Patients With Von Willebrand Disease
|
||
| Completed |
NCT01224808 -
Extension Study of Biostate in Subjects With Von Willebrand Disease
|
Phase 3 | |
| Completed |
NCT00805051 -
Acquired Von Willebrand Syndrome in Severe Aortic Stenosis
|
N/A | |
| Withdrawn |
NCT00694785 -
A Study of the Pharmacokinetics, Pharmacodynamics, and Safety of ARC1779 Injection in Patients With Von Willebrand Disease Type 2B
|
Phase 2 | |
| Completed |
NCT00168090 -
Study of Safety and Efficacy of Antihemophilic Factor/Von Willebrand Factor Complex in Surgical Subjects With Von Willebrand Disease (vWD)
|
Phase 4 | |
| Completed |
NCT02246881 -
A Study to Compare the Pharmacokinetics and Safety of Current Factor VIII Concentrate and Optivate® in Haemophilia A.
|
Phase 3 | |
| Completed |
NCT04657887 -
Registry of Patients With Von WilLEbrand Disease Treated With Voncento®
|
||
| Withdrawn |
NCT00630448 -
Collection of Blood in Normal Subjects and Subjects With Von Willebrand Disease (VWD)
|
N/A | |
| Terminated |
NCT00387192 -
A Study With OPTIVATE® in People With Von Willebrand Disease
|
Phase 3 | |
| Completed |
NCT02973087 -
rVWF IN PROPHYLAXIS
|
Phase 3 | |
| Completed |
NCT01410227 -
Pharmacokinetics, Safety and Efficacy of Recombinant Von Willebrand Factor (rVWF) in the Treatment of Bleeding Episodes in Von Willebrand Disease (VWD)
|
Phase 3 | |
| Completed |
NCT01949220 -
Willebrand International Non-interventional Global Surveillance
|
||
| Completed |
NCT01589848 -
Study on Von Willebrand Disease and Hemophilia in Cuenca, Ecuador
|
N/A | |
| Completed |
NCT00941616 -
Study of a pd VWF/FVIII Concentrate, Biostate®, in Subjects With Von Willebrand Disease
|
Phase 2/Phase 3 | |
| Completed |
NCT00557908 -
The Von Willebrand Disease (VWD) International Prophylaxis Study
|
N/A |